Abbott gets $1.5 million from Ohio for new plant; Bausch + Lomb buying ISTA;

> Ohio development officials have kicked in a $1.5 million loan toward the $270 million manufacturing project that Abbott Laboratories ($ABT) expects to open in the Dayton area late next year. Story

> Bausch + Lomb, ($BOL) which was already manufacturing most of the eye medicines sold by ISTA Pharmaceuticals ($ISTA), will acquire the Irvine, CA, company for $500 million. The two expect to consummate the deal, which is already approved by both boards, in the second quarter. Story

> Contract manufacturer PharmaForm, which has been working with Corcept Therapeutics ($CORT) on the development of the drug Korlym, has been given the contract to manufacture the product now that it has been approved by the FDA for the treatment of endogenous Cushing's syndrome. Article

> Environmentalists are criticizing EPA's proposed $204 million cleanup plan for a portion of the former Wyeth American Cyanamid site in Bridgewater, NJ, now owned by Pfizer ($PFE). Story

> Medical devicemaker Biomet will fork over $22.7 million to settle U.S. criminal and civil allegations that for more than 8 years it bribed government doctors in Argentina, Brazil and China to get business from hospitals. Story

> A study found that St. Jude Medical's ($STJ) recalled Riata wires may have additional issues that have led to "multiple defects that led to melted conductors, electrical abnormalities and shocks" according to a study, Bloomberg reports. Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.